Advances and Novel Multidisciplinary Strategies for Breast Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Causes, Screening and Diagnosis".

Deadline for manuscript submissions: closed (15 July 2024) | Viewed by 2724

Special Issue Editor


E-Mail Website
Guest Editor
Department of Breast and Endocrine Surgery, Nagoya University Graduate School of Medicine, Showa-ku, Nagoya 466-8550, Japan
Interests: breast cancer; surgical oncology; medical oncology; translational research

Special Issue Information

Dear Colleagues,

To conquer breast cancer, the cancer with the highest incidence among women worldwide, a multidisciplinary approach including prevention, early detection, optimal treatment strategies, and survivorship is essential. In the field of treatment, it is expected to practice an individualized strategy that balances local therapy (e.g., surgery and radiotherapy) with systemic medical therapy, and it is important to integrate the latest wisdom and skills of various medical specialists. Systemic combined immunotherapy using new immune checkpoint inhibitors has been standardized not only for advanced or metastatic disease but also for perioperative adjuvant treatment to prevent recurrence through the elimination of micrometastases, the progress in treatment optimization being based on cancer genome information, the announcement of new effective drugs such as ADC (antibody-drug conjugate), and novel therapeutic interventions based on gene mutation genetic mutation information detected in peripheral blood, for example, guaranteed by advances in molecular biological research methods; all aspects are expected to improve the prognosis. 

In the surgical field, new techniques such as robotic surgery and radiofrequency coagulation therapy to avoid skin incision have been developed, and the possibility of non-surgery with preoperative systemic therapy for highly chemotherapy-sensitive subtypes is being explored. Of course, advances in prophylactic resection for patients with BRCA pathological variants and reconstructive surgery cannot be overlooked. 

Supporting the practice of personalized treatment is the cooperation of radiologists and pathologists who provide more precise and sophisticated imaging and pathological diagnosis, and advances in those fields are also important. 

As treatment outcomes improve, it is also important to address supportive care and survivorship to avoid side effects, especially long-term toxicity, minimize the impact on daily life, and enhance quality of life. Collaboration with nurses, pharmacists, and other medical staff can provide the best care for patients. 

In addition, there are great expectations for progress in basic medical and epidemiological research to elucidate carcinogenic mechanisms, promote translational research, and avoid carcinogenic risks.    

We invite submissions of the latest information from your research and review articles from various professions and fields that support breast cancer patients, which are truly appropriate for the advances and novel multidisciplinary strategies for breast cancer.

Prof. Dr. Norikazu Masuda
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • conquering breast cancer
  • personalized therapy
  • escalation and de-escalation
  • multidisciplinary strategy
  • new devices for surgery
  • molecular diagnosis
  • prevention
  • survivorships

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Other

23 pages, 4959 KiB  
Article
Brief Magnetic Field Exposure Stimulates Doxorubicin Uptake into Breast Cancer Cells in Association with TRPC1 Expression: A Precision Oncology Methodology to Enhance Chemotherapeutic Outcome
by Viresh Krishnan Sukumar, Yee Kit Tai, Ching Wan Chan, Jan Nikolas Iversen, Kwan Yu Wu, Charlene Hui Hua Fong, Joline Si Jing Lim and Alfredo Franco-Obregón
Cancers 2024, 16(22), 3860; https://doi.org/10.3390/cancers16223860 - 18 Nov 2024
Viewed by 547
Abstract
Background/Objectives: Doxorubicin (DOX) is commonly used as a chemotherapeutic agent for the treatment of breast cancer. Nonetheless, its systemic delivery via intravenous injection and toxicity towards healthy tissues commonly result in a broad range of detrimental side effects. Breast cancer severity was [...] Read more.
Background/Objectives: Doxorubicin (DOX) is commonly used as a chemotherapeutic agent for the treatment of breast cancer. Nonetheless, its systemic delivery via intravenous injection and toxicity towards healthy tissues commonly result in a broad range of detrimental side effects. Breast cancer severity was previously shown to be correlated with TRPC1 channel expression that conferred upon it enhanced vulnerability to pulsed electromagnetic field (PEMF) therapy. PEMF therapy was also previously shown to enhance breast cancer cell vulnerability to DOX in vitro and in vivo that correlated with TRPC1 expression and mitochondrial respiratory rates. Methods: DOX uptake was assessed by measuring its innate autofluorescence within murine 4T1 or human MCF7 breast cancer cells following magnetic exposure. Cellular vulnerability to doxorubicin uptake was assessed by monitoring mitochondrial activity and cellular DNA content. Results: Here, we demonstrate that 10 min of PEMF exposure could augment DOX uptake into 4T1 and MCF7 breast cancer cells. DOX uptake could be increased by TRPC1 overexpression, whereas inhibiting the activity of TRPC1 channels with SKF-96356 or genetic knockdown, precluded DOX uptake. PEMF exposure enhances DOX-mediated killing of breast cancer cells, reducing the IC50 value of DOX by half, whereas muscle cells, representative of collateral tissues, were less sensitive to PEMF-enhanced DOX-mediated cytotoxicity. Vesicular loading of DOX correlated with TRPC1 expression. Conclusions: This study presents a novel TRPC1-mediated mechanism through which PEMF therapy may enhance DOX cytotoxicity in breast cancer cells, paving the way for the development of localized non-invasive PEMF platforms to improve cancer outcomes with lower systemic levels of DOX. Full article
(This article belongs to the Special Issue Advances and Novel Multidisciplinary Strategies for Breast Cancer)
Show Figures

Graphical abstract

Other

Jump to: Research

19 pages, 3348 KiB  
Systematic Review
Efficacy of Treatment for Metastatic Hormone-Sensitive Prostate Cancer: An Umbrella Review of Systematic Reviews and Meta-Analyses
by Pokket Sirisreetreerux, Napaphat Poprom, Pawin Numthavaj, Sasivimol Rattanasiri and Ammarin Thakkinstian
Cancers 2023, 15(24), 5714; https://doi.org/10.3390/cancers15245714 - 6 Dec 2023
Viewed by 1773
Abstract
Purpose: This umbrella review focused on evaluating the efficacy and adverse events of the metastatic hormone-sensitive prostate cancer patients receiving any treatment regimens, including ADT alone or combination treatments. Methods: This study conducted an umbrella review following the PRISMA 2020 checklist, aiming to [...] Read more.
Purpose: This umbrella review focused on evaluating the efficacy and adverse events of the metastatic hormone-sensitive prostate cancer patients receiving any treatment regimens, including ADT alone or combination treatments. Methods: This study conducted an umbrella review following the PRISMA 2020 checklist, aiming to summarize the available studies to evaluate the efficacy of medical treatments for metastatic hormone-sensitive prostate cancer. A literature search was performed to identify systematic reviews and meta-analyses (SRMAs) that included only randomized controlled trials (RCTs) up to September 2023. This study summarized their findings, evaluated overlapping data (i.e., the same RCTs were included in >one SRMA), tested for excessive significance (i.e., observed number of statistically significant studies > expected number by chance) and assessed the quality of the studies. Results: A total of 4191 studies were identified, but only 27 were included. Among those 27 studies, 12 were network meta-analyses and 15 were direct meta-analyses. Most studies showed no statistically significant difference in overall mortality among GnRH agonists, antagonists and bilateral orchiectomy. Combination treatment is more beneficial than ADT alone in both OS and PFS outcomes with more adverse events. Nevertheless, there is no OS advantage of any combination regimen over the others. Conclusion: Combination treatments demonstrated clear benefits in OS and PFS over ADT alone with more AEs. Further studies are needed to compare among combination treatments. Full article
(This article belongs to the Special Issue Advances and Novel Multidisciplinary Strategies for Breast Cancer)
Show Figures

Figure 1

Back to TopTop